All News

The addition of radiation after surgery improved clinical outcomes while not increasing severe late toxicity in this setting.

The review summarizes results from the OPTIMA II, ATLAS, and ENVISION trials.

Here’s a look back at notable news between July and September 2025.

Joy Maulik, CRNP, speaks with J. Brandon Arruda, APRN, AGNP-C, CUNP, about the evolving role of advanced practice providers in urology.

Take a look back at the notable regulatory decisions in benign urology between July and September.

The Expert APProach: Conversations in Uro-Oncology, hosted by Joy Maulik, CRNP, is the latest multimedia program from Urology Times.

We recap notable headlines from last month in the urologic oncology space.

We recap notable headlines from last month in the benign urology space.

Jason M. Hafron, MD, CMO, reflects on the most impactful recent developments in prostate cancer and offers insight into where the field is headed.

The device features a 12 French working channel, the largest of any flexible single-use cystoscope.

Daniel Spratt, MD, presented data validating the PAM50 gene expression signature as the first predictive biomarker to guide hormone therapy in prostate cancer.

A comprehensive guide to the key regulatory decisions and conferences slated for the last few months of the year.

According to the authors, CAN-2409 may represent the first new treatment option for men with localized prostate cancer in over 2 decades.

The PREDICT-RT trial is evaluating intensified or de-intensified concurrent hormone therapy and radiation regimens in high-risk prostate cancer.

Take a look through the key trials investigating BCG/ICI combinations in BCG-naïve NMIBC.

Take a closer look at what urologists can expect from the LBAs that will headline ESMO 2025.

The study is designed to evaluate the safety, efficacy, tolerability, and pharmacokinetics of FG-3246 in patients with mCRPC.

Martin B. Richman, MD, MBA, FACS, outlines recent advancements in BPH, with an emphasis on the importance of a patient-focused approach to care.

A major focus of the discussion is the integration of advanced prostate cancer therapeutics into urology offices.

This clearance adds onto a previous indication for the BioTraceIO platform in liver tumor ablation.

The approval is supported by data from the phase 3 MK-3475A-D77 trial.

The Altaviva device is a minimally invasive implantable tibial neuromodulation therapy for patients with urge urinary incontinence.

Among the topics covered are BCG dosing and maintenance regimens.

According to the authors, these findings suggest that FloStent could serve as an effective interim solution for men who are awaiting TURP.

The phase 2 trial has shown encouraging safety and efficacy results for carotuximab and apalutamide in patients with mCRPC.

Kanika Searvance, MD, and Yasin Bhanji, MD, discuss the evolution of BPH care.